{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostatic+Cancer+Metastatic", "query": { "condition": "Prostatic Cancer Metastatic" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1290, "total_pages": 129, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostatic+Cancer+Metastatic&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-24T07:25:19.690Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04363164", "title": "Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration Resistant Metastatic Prostate Cancer" ], "interventions": [ { "name": "Testosterone cypionate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Testosterone enanthate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "MALE", "summary": "18 Years to 90 Years · Male only" }, "enrollment_count": 150, "start_date": "2020-08-19", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-07-24T07:25:19.690Z", "location_count": 6, "location_summary": "San Diego, California • Baltimore, Maryland • Boston, Massachusetts + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04363164" }, { "nct_id": "NCT00571675", "title": "A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone Refractory Prostate Cancer" ], "interventions": [ { "name": "AT-101, prednisone and docetaxel", "type": "DRUG" }, { "name": "placebo, prednisone and docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascenta Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2007-10", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2010-11-09", "last_synced_at": "2026-07-24T07:25:19.690Z", "location_count": 24, "location_summary": "Colorado Springs, Colorado • New Port Richey, Florida • Ocoee, Florida + 21 more", "locations": [ { "city": "Colorado Springs", "state": "Colorado" }, { "city": "New Port Richey", "state": "Florida" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Fishers", "state": "Indiana" }, { "city": "Burnsville", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00571675" }, { "nct_id": "NCT03821792", "title": "Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Prostate Carcinoma", "Prostate Adenocarcinoma", "Prostate Carcinoma Metastatic in the Bone", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2019-07-22", "completion_date": "2026-10-11", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-07-24T07:25:19.690Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03821792" }, { "nct_id": "NCT01183663", "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2010-08", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-07-24T07:25:19.690Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183663" }, { "nct_id": "NCT00452387", "title": "Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Prostate Cancer" ], "interventions": [ { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accelerated Community Oncology Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 22, "start_date": "2007-05", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2011-09-16", "last_synced_at": "2026-07-24T07:25:19.690Z", "location_count": 10, "location_summary": "La Verne, California • Atlanta, Georgia • Macon, Georgia + 7 more", "locations": [ { "city": "La Verne", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Macon", "state": "Georgia" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Billings", "state": "Montana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00452387" }, { "nct_id": "NCT00101972", "title": "RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "monoclonal antibody RAV12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2004-12", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2022-02-22", "last_synced_at": "2026-07-24T07:25:19.690Z", "location_count": 5, "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101972" }, { "nct_id": "NCT00005028", "title": "Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "bryostatin 1", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 46, "start_date": "2000-05", "completion_date": "2006-07", "has_results": false, "last_update_posted_date": "2019-11-04", "last_synced_at": "2026-07-24T07:25:19.690Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Winston-Salem, North Carolina • Philadelphia, Pennsylvania + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "York", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005028" }, { "nct_id": "NCT01240551", "title": "F-18 Sodium Fluoride in Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Neoplasm" ], "interventions": [ { "name": "F-18 NaF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 60, "start_date": "2010-11-30", "completion_date": "2013-05-31", "has_results": true, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-07-24T07:25:19.690Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01240551" }, { "nct_id": "NCT05864144", "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Advanced Solid Tumor", "Head and Neck Cancer", "Breast Cancer", "Colon Cancer", "Pancreatic Cancer", "Gastric Cancer", "Esophageal Cancer", "Prostate Cancer", "Uterine Cancer", "Cervix Cancer", "Ovarian Cancer", "Kidney Cancer", "Bladder Cancer", "Thyroid Cancer", "Melanoma", "Sarcoma", "Advanced Cancer", "Metastatic Cancer", "Refractory Cancer", "Non Small Cell Lung Cancer", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "SNS-101 (anti-VISTA)", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sensei Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2023-05-31", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-08-15", "last_synced_at": "2026-07-24T07:25:19.690Z", "location_count": 10, "location_summary": "Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05864144" }, { "nct_id": "NCT07050433", "title": "COMPASS Study for Metastatic Castration-resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "CXCR2 as a biomarker", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 48, "start_date": "2025-08-07", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-07-24T07:25:19.690Z", "location_count": 3, "location_summary": "San Francisco, California • Ann Arbor, Michigan • Durham, North Carolina", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07050433" } ] }